diaDexus, Inc. – ‘8-K’ for 10/21/02 – EX-99.1

On:  Tuesday, 10/22/02, at 2:13pm ET   ·   For:  10/21/02   ·   Accession #:  1169232-2-2206   ·   File #:  0-26483

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                         4      9K 
 2: EX-99.1     Press Release Issued October 21, 2002                  2     10K 

EX-99.1   —   Press Release Issued October 21, 2002

EX-99.1
1st Page of 2
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
Exhibit 99.1                                                                    

 VaxGen's Phase III Trial in Thailand Clears Final

 Scheduled Safety Review

BRISBANE, Calif., Oct. 21 -- The independent board that oversees VaxGen, Inc.'s 
clinical trials completed the final safety and conduct review of the company's  
Phase III trial in Thailand and once again concluded that the study was being   
conducted appropriately and that VaxGen's AIDS vaccine candidate appears safe,  
VaxGen, Inc. (Nasdaq: VXGN) announced today.                                    

VaxGen is conducting two Phase III trials, one in Thailand and another in North 
America and Europe. The oversight board, or Data and Safety Monitoring Board    
(DSMB), completed its final safety review of the trial in North America and     
Europe in April 2002 and therefore focused solely on the trial in Thailand in   
its most recent evaluation.                                                     

In its seventh review of the Thai trial, the DSMB found that VaxGen's AIDS      
vaccine candidate, AIDSVAX B/E, continues to exhibit a very good safety profile.
More than 32,000 injections of AIDSVAX have been administered since it entered  
human clinical trials. VaxGen is testing AIDSVAX B/B in North American and      
Europe.                                                                         

Retention of volunteers in the Thai study remained above expectations. On an    
annualized basis, 96.7% of the volunteers in the trial continued to participate 
as of September 15, 2002.                                                       

The DSMB also conducted an interim analysis of efficacy using data from the     
trial in Thailand and recommended that the study continue to its planned        
conclusion in the second half of 2003. The DSMB would have recommended          
concluding the trial prematurely if the vaccine had proven effective ahead of   
schedule. The DSMB, which is composed of prominent scientists, researchers,     
clinicians, AIDS specialists, vaccinologists, biostatisticians and an ethicist, 
disclosed no information regarding vaccine efficacy.                            

VaxGen expects to announce primary efficacy results from the trial in North     
America and Europe in the first quarter of 2003 and similar results from the    
study in Thailand in the second half of 2003.                                   

EX-99.1
Last Page of 2
TOC
1st
Previous
Next
↓Bottom
Just 2nd
About VaxGen                                                                    

VaxGen is focused on the commercial development of biologic products for the    
prevention and treatment of human infectious diseases and is currently          
developing vaccines against HIV/AIDS and anthrax. VaxGen is the only company    
with HIV/AIDS vaccine candidates in Phase III clinical trials. The two trials,  
involving nearly 8,000 volunteers in the United States, Canada, the Netherlands,
Puerto Rico and Thailand, are designed to determine if VaxGen's AIDSVAX         
investigational vaccines can prevent humans from becoming infected with HIV, the
virus that causes AIDS. VaxGen is also developing an anthrax vaccine for the    
U.S. National Institutes of Health.                                             

Additionally, VaxGen is the largest shareholder of Celltrion, Inc., a joint     
venture created to provide manufacturing services, principally for products     
produced in mammalian cell culture, including AIDSVAX. VaxGen is located in     
Brisbane, Calif. For more information, please visit the company's web site at:  
www.vaxgen.com. AIDSVAX(R) is a registered trademark of VaxGen.                 

Note: This press release contains "forward-looking statements" within the       
meaning of the federal securities laws. These forward-looking statements include
without limitation statements regarding the progress, costs, timing and results 
of the anthrax contract with NIH; our and our subcontractors' ability to develop
a new anthrax vaccine in accordance with government specifications, or at all;  
our ability to secure a government contract to manufacture and supply an anthrax
vaccine, if development of such a vaccine were successful; the progress, costs  
and results of our Phase III clinical trials; domestic and foreign regulatory   
approvals of AIDSVAX; the ability to manufacture and supply AIDSVAX or any other
vaccine or product; our ability to commercialize AIDSVAX or any other vaccine or
product; our ability to manage our foreign manufacturing joint venture; the     
timing, and announcement of results, of either of our Phase III clinical trials,
including the timing and announcement of results from any interim analyses; our 
beliefs regarding the future success of AIDSVAX and other products currently    
under development or proposed to be developed; and the ability of our Celltrion 
joint venture to raise necessary funding for execution of its business plan.    
These statements are subject to risks and uncertainties that could cause actual 
results and events to differ materially from those anticipated. Reference should
be made to VaxGen's Quarterly Report on Form 10-Q, filed with the Securities and
Exchange Commission on August 14, 2002, under the heading "Risk Factors" and to 
VaxGen's Annual Report on Form 10-K, filed with the Securities and Exchange     
Commission on April 1, 2002, under the heading "Business" for a more detailed   
description of such factors. Readers are cautioned not to place undue reliance  
on these forward-looking statements that speak only as of the date of this      
release. VaxGen undertakes no obligation to update publicly any forward-looking 
statements to reflect new information, events, or circumstances after the date  
of this release or to reflect the occurrence of anticipated events.             

Dates Referenced Herein   and   Documents Incorporated by Reference

				Referenced-On Page
This ‘8-K’ Filing		Date		First		Last			Other Filings
Filed on:		10/22/02
For Period End:		10/21/02
		9/15/02		1
		8/14/02		2					10-Q
		4/1/02		2					10-K
									List all Filings